Piper Sandler initiated coverage of Opus Genetics (IRD) with an Overweight rating and $7 price target The company has demonstrated early efficacy data for its lead gene therapy program, OPGx-LCA5, in Leber congenital amaurosis type 5, where there are currently no treatment options and a high unmet need, the analyst tells investors in a research note. In addition, Piper says Opus’ second gene therapy program, OPGx-BEST1 for BEST1-related inherited retinal diseases, has promising preclinical data.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Buy These 3 Penny Stocks Now, Say Five-Star Analysts
- Opus Genetics doses first participant in OPGx-BEST1 Phase 1/2 trial
- Promising Advancements in Opus Genetics’ Retinal Disease Platform Support Buy Rating
- Opus Genetics: Buy Rating Backed by Strong Financials, Regulatory Support, and Promising Study Progress
- Opus Genetics reports Q3 EPS (25c) vs (29c) last year